U.S. markets open in 7 hours 9 minutes
  • S&P Futures

    3,939.25
    +2.50 (+0.06%)
     
  • Dow Futures

    33,654.00
    +29.00 (+0.09%)
     
  • Nasdaq Futures

    11,513.75
    +4.25 (+0.04%)
     
  • Russell 2000 Futures

    1,810.80
    +2.80 (+0.15%)
     
  • Crude Oil

    73.11
    +1.10 (+1.53%)
     
  • Gold

    1,797.90
    -0.10 (-0.01%)
     
  • Silver

    22.91
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0515
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • Vix

    22.68
    +0.51 (+2.30%)
     
  • GBP/USD

    1.2201
    -0.0004 (-0.04%)
     
  • USD/JPY

    136.7440
    +0.2200 (+0.16%)
     
  • BTC-USD

    16,836.21
    +10.63 (+0.06%)
     
  • CMC Crypto 200

    395.24
    -6.80 (-1.69%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Omaha-Based MRI Medical Device Company, Bot Image, Receives FDA Clearance for Artificial Intelligence Software Used in Detection and Diagnosis of Prostate Cancer

OMAHA, Neb., Aug. 8, 2022 /PRNewswire/ -- Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx). The tool, called ProstatID, combines artificial intelligence with traditional MRI scanning.

Bot Image Logo
Bot Image Logo

"Prostate cancer screening and detection methods adoption has changed little over the past 30 years, despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods," says the company founder and CEO Dr. Randall W. Jones. "Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone. ProstatID represents an exciting step in the fight to save lives."

Trained by analyzing thousands of MRI image sets, radiological interpretations, guided biopsies, and pathology lab results, the software's algorithm recognizes and measures the volume of the prostate gland, and detects suspicious cancerous lesions - assigning a cancer probability to each one, and suggests a diagnostic case score known as PI-RADS (Prostate Imaging Reporting and Data Sytem) score. This was proven in two clinical studies (involving 25 radiologists from around the US) to significantly improve radiologic interpretation accuracy as measured by improved detection and fewer false positives when radiologists used the aid of the CAD. This demonstrates a tremendous savings of time and cost for the patient and provider, potentially saving lives in the process via early and accurate detection.

ProstatID's ability to detect lesions and assign a cancer probability to prostate MRI cases goes far beyond existing technologies which have improved on-screen formatting of prostate MRI cases and segmentations of a patient's prostate but stopped short of aiding in detection and diagnosis.

The computer-aided design tool is currently available for use as a Software-as-a-service (SaaS) device which requires only a secure VPN tunnel connection between the radiology department server or MRI system and the cloud-based ProstatID server. The software and connectivity are both HIPAA compliant and cyber-secure.

"With FDA clearance, the path for implementation is open", says Jones, "and hospitals and radiological clinics can connect in as little as one hour of IT effort, and begin bringing this exciting technology to their patients".

Please contact Melanie Jones mjones@botimageai.com for further information.

ABOUT BOT IMAGE

Bot Image, Inc.'s mission is to blend artificial intelligence (AI) with other diagnostic mediums and bring about substantial improvements in clinical outcomes where it matters most: Improved cancer screening, detection, classification, and grading using non-invasive imaging technologies such as MRI and CT. The Omaha-based medical imaging software company's first product, ProstatID, blends AI with MRI to detect potentially cancerous lesions, assigning a cancer probability score to each, and aid physician's in the patient diagnosis.

Dr. Randall W. Jones (www.drrandallwjones.com), founder and CEO of Bot Image, is a leader in the field of MRI device development as well as prostate cancer with decades of experience in the respective specialties. Jones notes that one in eight men develop prostate cancer in their lifetime and about 30,000 die annually — figures that can be reduced by more accurate early detection and diagnosis. He further notes that by using AI to improve detection and diagnostic accuracies, billions of healthcare dollars can be saved annually by avoiding unwarranted biopsies and treatments; and in the case of prostate cancer, improved treatment planning could save countless unnecessary radical prostatectomies that have a high degree of undesirable side effects such as incontinence and/or impotence.

Jones stated that the company is expanding its clinical research relationships with key academic hospitals including co-authoring peer-reviewed journal articles, sponsored research studies, and continued SaaS services. Bot Image is also working to create several additional software products to improve the early detection and accuracy of other diseases (such as stroke assessment and liver disease) using MRI and artificial intelligence technology. The company is currently negotiating several Use and Development contracts with large service provider networks and expects exponential growth over the next few years.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/omaha-based-mri-medical-device-company-bot-image-receives-fda-clearance-for-artificial-intelligence-software-used-in-detection-and-diagnosis-of-prostate-cancer-301600822.html

SOURCE Bot Image Inc.